insights_auto
Mengapa OPHLY turun 2,31%?
Pelajari Lebih Lanjutchevron_right
OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
US$4,65
arrow_downward
-2,31%(-0,11) 1 HR
14 Okt, 16.00.00 GMT-4 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk OPHLY...
Pembukaan
US$4,71
Tinggi
US$4,93
Rendah
US$4,63
Kapitalisasi pasar
1,16Â T
Volume rata-rata
62,09Â rb
Volume
35,04Â rb
Harga tinggi dalam 52 minggu terakhir
US$5,75
Harga rendah dalam 52 minggu terakhir
US$3,82
Beta
0,21
Saham beredar
1,50Â M
Jumlah karyawan
4Â rb
Pembukaan
US$4,71
Tinggi
US$4,93
Rendah
US$4,63
Kapitalisasi pasar
1,16Â T
Volume rata-rata
62,09Â rb
Volume
35,04Â rb
Harga tinggi dalam 52 minggu terakhir
US$5,75
Harga rendah dalam 52 minggu terakhir
US$3,82
Beta
0,21
Saham beredar
1,50Â M
Jumlah karyawan
4Â rb
Artikel berita
Dari sumber web dan partner berita
Pluang
·
16 jam yang lalu
Opsi S&P 500 kuasai volume $640 juta di Hyperca...
BeInCrypto
·
2 jam yang lalu
S&P 500 Masuk ke Periode Musiman Terkuat
Pluang
·
8 jam yang lalu
Citi target S&P 500 di 8.100 jika sektor sensit...
Rmol.id
·
2 jam yang lalu
Wall Street Anjlok, Nasdaq Tertekan Inflasi AS
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Tentang Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Karyawan4,21Â rb
Didirikan1717
Kantor PusatOsaka, Prefektur Osaka, Jepang
Sektor-
Situsono-pharma.com